An Austin biotech company is laying off a third of its staff following news that its primary drug candidate didn't produce ...

Tran Le was an engineering student at Stanford University when she tried to enroll in a clinical trial for her chronic ...

An estimated 610,000 people in the US died from cancer last year. That’s almost the same amount of people who perished in the country’s four-year civil war. At least two million more people were ...

Imagine having a digital carbon copy of yourself that physicians could use to predict long-term risks for disease, assess how your body may respond to treatment, and simulate surgeries in advance. A ...

The global artificial intelligence in clinical trials market, valued at US$1.20 billion in 2023, is forecasted to grow at a ...

US-based Halia Therapeutics’ new therapy will be put to a six-month-long trial that will involve 60 patients with type 2 ...

A multidisciplinary team of University of Miami researchers studying factors associated with health outcomes and disease risk in the Hispanic community has received a $21 million grant from the ...

Researchers have discovered that healthy skin — once thought to be a passive barrier — can actually produce antibodies that fight off infections. It’s hoped that the finding could one day lead to the ...

The typical cost of developing new medications may not be as high as generally believed, with a few ultra-costly medications ...

As a wellness writer who spends a bit too much time analyzing indigent lists and scrolling on TikTok, there’s hardly anything ...

The US Food and Drug Administration has issued guidance urging sponsors and trial sites to consider the necessity of the ...

NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy. Initial data from Phase 1b/2 ex-U.S. study NEXICART-1 has demonstrated high complete response rates ...